Neos Therapeutics, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|---|
| Revenue | $14.6M | $10.7M | $27.1M | $10.0M | $428,000 | $758,000 |
| Operating income | −$10.4M | −$43.5M | −$56.5M | −$75.8M | −$26.6M | −$18.5M |
| Net income | −$16.9M | −$51.7M | −$65.8M | −$82.8M | −$30.8M | −$20.8M |
| Total assets | $90.9M | $111.4M | $104.1M | $80.1M | $122.5M | $45.2M |
| Total liabilities | — | — | — | — | — | — |
| Equity | −$6.1M | $7.8M | $8.9M | −$966,000 | $78.4M | −$78.8M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 49.7M | 29.0M | 22.6M | 16.0M | 16.0M | 882,954 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- −71.2%
- Net margin
- −115.5%
- Return on equity
- 275.7%
- Return on assets
- −18.6%
- Return on capital (ROCE)
- −37.8%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $-0.12
- Revenue growth (YoY)
- 36.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Accruals / assets
- −6.7%clean
- Piotroski F-Score
- 4/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 3 good- Negative shareholder equity
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Limongelli John MOfficer — SVP & General Counsel | Mar 19, 2021 | D | 83,015 | — |
| Robinson James A. Jr.Director | Mar 19, 2021 | D | 23,453 | — |
| Mclaughlin Gerald W.Officer — Chief Executive Officer | Mar 19, 2021 | D | 270,171 | — |
| Hecht BethDirector | Mar 19, 2021 | D | 23,453 | — |
| Schmid John P.Director | Mar 19, 2021 | D | 23,453 | — |
| Fong BryantDirector | Mar 19, 2021 | D | 24,953 | — |
| Szyper Linda MDirector | Mar 19, 2021 | D | 23,453 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Shareholder voteMar 22, 2021
- Entered a material agreement · New financial obligation · Delisting / listing-standard notice · Unregistered equity saleFeb 8, 2021
- Regulation FD disclosureJan 11, 2021
- Delisting / listing-standard noticeDec 30, 2020
- Entered a material agreement · Regulation FD disclosureDec 11, 2020
- Regulation FD disclosureDec 10, 2020
- Results of operationsNov 9, 2020
- Results of operationsAug 10, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12BFORM 15-12BMar 30, 2021
- EFFECTMar 25, 2021
- EFFECTMar 25, 2021
- EFFECTMar 25, 2021
- EFFECTMar 25, 2021
- 8-KCURRENT REPORTMar 22, 2021
- 425CURRENT REPORTMar 22, 2021
- 4OWNERSHIP DOCUMENTMar 19, 2021
- 4OWNERSHIP DOCUMENTMar 19, 2021
- 4OWNERSHIP DOCUMENTMar 19, 2021
- 4OWNERSHIP DOCUMENTMar 19, 2021
- 4OWNERSHIP DOCUMENTMar 19, 2021
- 4OWNERSHIP DOCUMENTMar 19, 2021
- 4OWNERSHIP DOCUMENTMar 19, 2021
- 4OWNERSHIP DOCUMENTMar 19, 2021
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.